THERAPY FOR COMPLICATIONS OF DIABETES

PROBLEM TO BE SOLVED: To provide a selective ETreceptor antagonist and a therapeutic combination used in a method for enhancing blood glucose control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome.SOLUTION: According to the present invention, for...

Full description

Saved in:
Bibliographic Details
Main Authors RODEN ROBERT L, RICHARD J GORCZYNSKI, GERBER MICHAEL J
Format Patent
LanguageEnglish
Japanese
Published 24.08.2017
Subjects
Online AccessGet full text

Cover

More Information
Summary:PROBLEM TO BE SOLVED: To provide a selective ETreceptor antagonist and a therapeutic combination used in a method for enhancing blood glucose control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome.SOLUTION: According to the present invention, for use in a method for treating diabetic nephropathy in a human subject having diabetic nephropathy, a medicine comprises atrasentan or a salt thereof in combination with an angiotensin-converting enzyme inhibitor or an angiotensin II receptor-blocking agent. Here, the method comprises administering to the subject at least one dose of atrasentan or a salt thereof and an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocking agent.SELECTED DRAWING: Figure 1 【課題】糖尿病性腎症及び/又はメタボリックシンドロームを有するヒトの対象において血糖管理及び/又はインスリン感受性を高めるための方法における使用のための選択的ETA受容体拮抗剤及び療法上の組み合わせの提供。【解決手段】糖尿病性腎症を有するヒト対象において糖尿病性腎症を治療する方法における使用のための、アトラセンタン又はその塩を、アンギオテンシン変換酵素阻害剤又はアンギオテンシンII受容体遮断剤と組み合わせてなる薬物であって、前記方法は、アトラセンタン又はその塩、及びアンギオテンシン変換酵素阻害剤又はアンギオテンシンII受容体遮断剤の少なくとも一つの用量を対象に投与することを含む、前記薬物。【選択図】図1
Bibliography:Application Number: JP20170035751